Survodutide (BI 456906): GLP1/GCGR agonist | MASH
Phase 2
Therapeutic Area: Cardio-renal-metabolic Diseases
Indication: MASH
Anchored in external partnership or acquisition
EMA PRIME Designation
US FDA Fast Track Designation
Boehringer Ingelheim is developing BI 456906, a novel glucagon receptor/GLP-1 receptor dual agonist, for the treatment of people living with overweight or obesity (Body Mass Index (BMI) ≥ 27 kg/m2) as well as for the treatment people living with of metabolic dysfunction-associated steatohepatatis (MASH).
The GLP-1/glucagon compound derived from the natural gut hormone oxyntomodulin activates both the GLP-1 and glucagon receptors that are critical to controlling metabolic functions. It is part of Boehringer Ingelheim’s research and development portfolio in the cardiometabolic disease areas.